Brain tissue removed during surgery reveals potential way to curb inflammation linked to Alzheimer's
Inflammatory conditions in the brain, including traumatic brain injury and degenerative diseases like Alzheimer's, could be targeted with an existing drug thanks to new research that shows it can work in brain cells.
Recent research published in the journal Brain has identified a potential new approach to targeting neuroinflammation, a hallmark of conditions like Alzheimer's disease, Parkinson's disease, and traumatic brain injury (TBI). A team led by professor Nicholas Barnes from the University of Birmingham found that blocking a receptor called P2X7 can significantly reduce inflammatory responses in human brain tissue.
This discovery could lead to the repurposing of existing drugs to combat neuroinflammation, which is believed to play a role in many chronic neurological and psychiatric disorders. The team developed a method to convert peripheral blood monocytes into microglia-like cells to study how these immune cells respond to inflammation signals in the brain.
By administering a P2X7 receptor antagonist to these cells, they successfully interrupted the inflammatory triggers that microglia release. This breakthrough could pave the way for clinical trials targeting patients with neurodegenerative conditions and TBI, conditions for which there are currently no effective pharmacological treatments to reduce neuroinflammation and its damaging effects.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
